SCHEMBL2226095

SCHEMBL2226095

COc1ccc(CNc2ncc(-c3cccc(Nc4cc(C)ccn4)n3)o2)cc1

nearest known ligand 0.46

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
KARS1 Q15046 9/20 0.46
CLK4 Q9HAZ1 5/20 0.42
DYRK1A Q13627 4/20 0.42
ALDH1A1 P00352 1/20 0.41
MAPK10 P53779 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
CLK1 P49759 1/20 0.41
NOS2 P35228 1/20 0.41
TP53 P04637 1/20 0.40
GAA P10253 1/20 0.40
MAPT P10636 1/20 0.40
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
POLB P06746 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2279296 0.89 KARS1 (0.52) KARS1NOS2MEN1KMT2APOLB
SCHEMBL2227897 0.79 KARS1 (0.47) KARS1ALDH1A1MAPK10SMN1; SMN2L3MBTL1
SCHEMBL2225285 0.79 KARS1 (0.47) KARS1ALDH1A1TP53MAPTMEN1
SCHEMBL2225286 0.79 KARS1 (0.47) KARS1ALDH1A1TP53MAPTMEN1
SCHEMBL14684146 0.75 KARS1 (0.48) KARS1CLK4ALDH1A1
SCHEMBL2227009 0.74 KARS1 (0.58) KARS1MEN1KMT2A
SCHEMBL2227056 0.74 KARS1 (0.58) KARS1CLK4MEN1KMT2A
SCHEMBL2354077 0.74 KARS1 (0.48) KARS1ALDH1A1MAPK10SMN1; SMN2L3MBTL1
SCHEMBL8422251 0.73 MEN1 (0.68) CLK4DYRK1AALDH1A1MAPK10SMN1; SMN2
SCHEMBL14673806 0.73 KARS1 (0.49) KARS1ALDH1A1SMN1; SMN2TP53GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2523952-B1 OXAZOLE KINASE INHIBITORS AB SCIENCE (FR) 2015-03-04 EP claimed
EP-2523952-A1 THIAZOLE AND OXAZOLE KINASE INHIBITORS AB Science (FR) 2012-11-21 EP claimed
WO-2011086085-A1 THIAZOLE AND OXAZOLE KINASE INHIBITORS AB SCIENCE (FR) 2011-07-21 WO claimed
EP-2523952-B1 OXAZOLE KINASE INHIBITORS AB SCIENCE (FR) 2015-03-04 EP disclosed
US-8962665-B2 Thiazole and oxazole kinase inhibitors AB SCIENCE (FR) 2015-02-24 US disclosed
US-8962665-B2 Thiazole and oxazole kinase inhibitors AB SCIENCE (FR) 2015-02-24 US disclosed
US-20130035331-A1 THIAZOLE AND OXAZOLE KINASE INHIBITORS AB SCIENCE (FR) 2013-02-07 US disclosed
US-20130035331-A1 THIAZOLE AND OXAZOLE KINASE INHIBITORS AB SCIENCE (FR) 2013-02-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130035331-A1 THIAZOLE AND OXAZOLE KINASE INHIBITORS SYK, LTK, MERTK KARS1 1099/4885CLK4 991/4885DYRK1A 192/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.